Please select the eligibility criteria that correspond to the clinical trial below.
Title: Endometrial Receptivity Enhancement Through Induced Injury and Repair During Ovarian Stimulation in an Antagonist Down-regulated Cycle
Brief Summary: A randomised controlled open-label clinical trial to assess the effect of artificially induced endometrial injury and repair during ovarian stimulation on the clinical pregnancy rate of an antagonist downregulated in-vitro fertilisation cycle


Options:
A: Inclusion Criteria:

* Fresh IVF/ICSI cycle
* Antagonist down-regulation
* Signed informed consent

Exclusion Criteria:

* Other known reasons for impaired implantation (i.e. hydrosalpinx, fibroid distorting the endometrial cavity, Asherman's syndrome, thrombophilia or endometrial tuberculosis)
* Oocyte donation acceptors
* Frozen egg transfers
* Embryos planned to undergo preimplantation genetic diagnosis (PGD)
* BMI \>35 or \<18
* Women already recruited for another trial on medically assisted procreation during the same cycle
* Women who have previously enrolled in the trial
* Those unable to comprehend the investigational nature of the proposed study
B: Inclusion Criteria:

* Patient undergoing IVF/CCS (no PGD banking)
* Patient meets ASRM guidelines for Double Embryo Transfer (DET)
* Donor Sperm OK
* AMH ≥ 1.2
* FSH ≤ 12
* BAFC ≥12
* Max 1 prior failed IVF cycle for patients 35-45 years old
* Patient \<35 years old MUST have 1 prior failed IVF cycle

Exclusion Criteria:

* Chronic endometrial insufficiency
* Use of oocyte donor or gestational carriers
* Medical contraindications to Double Embryo Transfer (DET)
* Male Factor (\<100,000 sperm or surgical sperm)
* Communicating hydrosalpinx (on HSG)
* Single gene disorders or sex selection
C: Inclusion Criteria:

* All patients medically cleared to do a fresh or frozen embryo transfer.
* Age up to 42 years

Exclusion Criteria:

* microsurgical epididymal sperm aspiration (MESA) and Testicular sperm extraction (TESE) patients
* At least one partner carrier of a chromosomal or genetic disease
* Abnormal ovarian reserve, defined as follicle stimulating hormone (FSH) of \>10 IU/L on day 2-4 of the cycle and anti-mullerian hormone (AMH) \< 1ng /ml (If only one of the two parameters altered then patients is acceptable). This is based on Mandy Katz abstract at American Society for Reproductive Medicine (ASRM) 2011 where they showed that these patients have 35% chance of having no euploid embryos - They are excluded only to make the study size smaller, otherwise, if an euploid embryo is found in these patients, they implant as well as patients with normal ovarian reserve. Not all centers do AMH testing - we recommend first to run FSH and only test AMH if FSH is abnormal.
* Egg donor cycle (sperm donor is acceptable)
* Gender selection cycles
* Thaw cycles
D: Inclusion Criteria:

* women who applied to our clinic due to infertility and who undergone one or more failed fresh IVF cycles previously has been included in our study for ICSI-ET (intracytoplasmic sperm injection-embryo transfer).

Exclusion Criteria:

* women with factors as hydrosalpenx, trombophilia, submucous myoma and found to have a negative impact on implantation

Answer: A